Results 31 to 40 of about 8,135 (150)

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY?

Рациональная фармакотерапия в кардиологии, 2015
The problem of varenicline use in patients with cardiovascular diseases is discussed. Results of large clinical trials and meta-analyses with varenicline have proven its high efficacy for treatment of nicotine addiction in adults and a small number of ...
Yu. V. Lukina, S. Yu. Martsevich
doaj   +3 more sources

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson, Thomas Parkhouse, Chloe Burke, Monika Halicka, Jennifer C. Palmer, Hend Gabr, Rebecca Wilson, Katie E. Webster, Francesca Spiga, Sarah Dawson, Deborah M. Caldwell, Jennifer Scott, Julian P. T. Higgins, Jelena Savović   +13 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Varenicline in the treatment of tobacco dependence

Neuropsychiatric Disease and Treatment, 2008
Karl Fagerström1, John Hughes21Smokers Information Centre, Fagerström Consulting AB, Berga Alle 1, 25452 Helsingborg, Sweden; 2University of Vermont, Burlington, Vermont, USAAbstract: Varenicline, a partial agonist of α4& ...
Karl Fagerström, John Hughes
doaj  

Nicotine receptor partial agonists for smoking cessation

São Paulo Medical Journal
BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist)
Kate Cahill, Lindsay F. Stead, Tim Lancaster, Igor Bastos Polonio   +3 more
doaj   +1 more source

Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink

Health Technology Assessment, 2020
Background: Smoking is the leading avoidable cause of illness and premature mortality. The first-line treatments for smoking cessation are nicotine replacement therapy and varenicline.
Neil M Davies, Amy E Taylor, Gemma MJ Taylor, Taha Itani, Tim Jones, Richard M Martin, Marcus R Munafò, Frank Windmeijer, Kyla H Thomas   +8 more
doaj   +1 more source

An integrated behavioral change model for smoking cessation in periodontal care: The four‐stage behavioral support staircase

Periodontology 2000, EarlyView.
Abstract Objectives Smoking tobacco is a critical modifiable risk factor for periodontal and peri‐implant diseases. This narrative review integrates established behavioral theories with communication‐based psychological processes to propose an evidence‐based model for smoking cessation support in periodontal care.
Christoph A. Ramseier
wiley   +1 more source